Reviewing Global Cord Blood Corporation (CO)’s and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI)’s results

Global Cord Blood Corporation (NYSE:CO) and Spectrum Pharmaceuticals Inc. (NASDAQ:SPPI), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the analyst recommendations, profitability, risk, institutional ownership, dividends, earnings and valuation of the two firms.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Global Cord Blood Corporation N/A 0.00 N/A 0.28 26.39
Spectrum Pharmaceuticals Inc. 109.33M 9.97 120.01M -0.60 0.00

Table 1 shows the top-line revenue, earnings per share (EPS) and valuation for Global Cord Blood Corporation and Spectrum Pharmaceuticals Inc.


Table 2 demonstrates the return on assets, net margins and return on equity of Global Cord Blood Corporation and Spectrum Pharmaceuticals Inc.

Net Margins Return on Equity Return on Assets
Global Cord Blood Corporation 0.00% 7.2% 3.8%
Spectrum Pharmaceuticals Inc. -109.77% 0% 0%

Volatility & Risk

A beta of 0.41 shows that Global Cord Blood Corporation is 59.00% less volatile than Standard and Poor’s 500. Spectrum Pharmaceuticals Inc.’s 170.00% more volatile than Standard and Poor’s 500 volatility due to the stock’s 2.7 beta.


9.7 and 9.6 are the respective Current Ratio and a Quick Ratio of Global Cord Blood Corporation. Its rival Spectrum Pharmaceuticals Inc.’s Current and Quick Ratios are 2.9 and 2.9 respectively. Global Cord Blood Corporation has a better chance of clearing its pay short and long-term debts than Spectrum Pharmaceuticals Inc.


Global Cord Blood Corporation pays out an annual dividend of $0.08 per share while its dividend yield is 1.09%. No dividend is paid out for Spectrum Pharmaceuticals Inc.

Analyst Recommendations

The next table highlights the shown recommendations and ratings for Global Cord Blood Corporation and Spectrum Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Global Cord Blood Corporation 0 0 0 0.00
Spectrum Pharmaceuticals Inc. 0 0 3 3.00

Spectrum Pharmaceuticals Inc. on the other hand boasts of a $30 consensus target price and a 200.60% potential upside.

Insider & Institutional Ownership

Roughly 17.4% of Global Cord Blood Corporation shares are held by institutional investors while 82% of Spectrum Pharmaceuticals Inc. are owned by institutional investors. Global Cord Blood Corporation’s share held by insiders are 49.6%. Competitively, 1.5% are Spectrum Pharmaceuticals Inc.’s share held by insiders.


Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Global Cord Blood Corporation 3.79% 17.68% 15.29% 6.79% -29.82% 14.57%
Spectrum Pharmaceuticals Inc. -8.02% -2.77% -21.14% -55.15% -47.79% 24.46%

For the past year Global Cord Blood Corporation was less bullish than Spectrum Pharmaceuticals Inc.


Global Cord Blood Corporation beats Spectrum Pharmaceuticals Inc. on 8 of the 12 factors.

Global Cord Blood Corporation, together with its subsidiaries, provides umbilical cord blood storage and ancillary services in the People's Republic of China. The company offers cord blood testing, processing, and storage services under the direction of subscribers; and tests, processes, and stores donated cord blood, as well as provides matching services. As of March 31, 2018, it had three operating cord blood banks in the Beijing municipality, the Guangdong province, and the Zhejiang province. The company was formerly known as China Cord Blood Corporation and changed its name to Global Cord Blood Corporation in March 2018. Global Cord Blood Corporation is based in Central, Hong Kong. Global Cord Blood Corporation is a subsidiary of Nanjing Ying Peng Hui Kang Medical Industry Investment Partnership (Limited Partnership).

Spectrum Pharmaceuticals, Inc. develops and commercializes oncology and hematology drug products. The company markets six drug products, including FUSILEV for patients with metastatic colorectal cancer and rescue after high-dose methotrexate therapy in osteosarcoma, and to diminish toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor to treat patients with relapsed or refractory PTCL; ZEVALIN injection for patients with follicular non-HodgkinÂ’s lymphoma; MARQIBO, a sphingomyelin/cholesterol liposome-encapsulated formulation for adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia; BELEODAQ injection for patients with relapsed or refractory PTCL; and EVOMELA for use as a conditioning treatment prior to autologous stem cell transplant in multiple myeloma patients. It is also developing ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer; and POZIOTINIB for treating breast and lung cancer. The company sells its drugs through a direct sales force in the United States; and through distributors in Europe. Spectrum Pharmaceuticals, Inc. has licensing and development agreement with Cell Therapeutics, Inc.; license agreement with Merck & Cie AG, Sloan-Kettering Institute, and Cydex Pharmaceuticals, Inc.; development and commercialization collaboration agreement with Allergan, Inc.; collaboration agreement with Nippon Kayaku Co., LTD.; licensing and collaboration agreement with Onxeo DK; and co-development and commercialization agreement with Hanmi Pharmaceutical Company. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is headquartered in Henderson, Nevada.